全文获取类型
收费全文 | 6726篇 |
免费 | 498篇 |
国内免费 | 24篇 |
专业分类
耳鼻咽喉 | 82篇 |
儿科学 | 162篇 |
妇产科学 | 100篇 |
基础医学 | 964篇 |
口腔科学 | 164篇 |
临床医学 | 646篇 |
内科学 | 1559篇 |
皮肤病学 | 85篇 |
神经病学 | 755篇 |
特种医学 | 262篇 |
外科学 | 1023篇 |
综合类 | 60篇 |
一般理论 | 5篇 |
预防医学 | 366篇 |
眼科学 | 133篇 |
药学 | 338篇 |
中国医学 | 8篇 |
肿瘤学 | 536篇 |
出版年
2023年 | 60篇 |
2022年 | 102篇 |
2021年 | 187篇 |
2020年 | 134篇 |
2019年 | 167篇 |
2018年 | 200篇 |
2017年 | 149篇 |
2016年 | 163篇 |
2015年 | 197篇 |
2014年 | 267篇 |
2013年 | 332篇 |
2012年 | 525篇 |
2011年 | 505篇 |
2010年 | 327篇 |
2009年 | 261篇 |
2008年 | 468篇 |
2007年 | 446篇 |
2006年 | 391篇 |
2005年 | 388篇 |
2004年 | 315篇 |
2003年 | 309篇 |
2002年 | 270篇 |
2001年 | 68篇 |
2000年 | 41篇 |
1999年 | 61篇 |
1998年 | 52篇 |
1997年 | 37篇 |
1996年 | 43篇 |
1995年 | 47篇 |
1994年 | 32篇 |
1993年 | 42篇 |
1992年 | 36篇 |
1991年 | 34篇 |
1990年 | 30篇 |
1989年 | 34篇 |
1988年 | 46篇 |
1987年 | 35篇 |
1986年 | 28篇 |
1985年 | 26篇 |
1984年 | 32篇 |
1983年 | 30篇 |
1982年 | 31篇 |
1981年 | 30篇 |
1979年 | 22篇 |
1978年 | 21篇 |
1975年 | 17篇 |
1974年 | 23篇 |
1973年 | 16篇 |
1972年 | 15篇 |
1970年 | 16篇 |
排序方式: 共有7248条查询结果,搜索用时 15 毫秒
71.
Skp2 protein expression in soft tissue sarcomas. 总被引:15,自引:0,他引:15
Andre M Oliveira Scott H Okuno Antonio G Nascimento Ricardo V Lloyd 《Journal of clinical oncology》2003,21(4):722-727
BACKGROUND: p45 S phase kinase-associated protein-2 (p45(skp2)), a member of the F-box family of proteins, is an important component of the Skp1-Cullin-F-box protein (SCF) ubiquitin-ligase complex (SCF(skp2)). The latter has been implicated in the ubiquitination and degradation of p27(kip1) (p27) and G(1)-S cell cycle progression. The expression and prognostic role of Skp2 in a large series of soft tissue sarcomas has not been previously investigated. METHODS: Clinicopathologic features and immunohistochemical expression of Skp2, p27, and Ki-67 proteins were studied in 182 cases of soft tissue sarcomas (American Joint Committee on Cancer stages II and III). Survival analyses were performed using the Kaplan-Meier method and the Cox regression model. RESULTS: The male to female ratio was 1.2:1, and the median age at the diagnosis was 53 years. The tumors were predominantly located in the lower extremities (n = 163; 90%) and had a median size of 9 cm. High Skp2 expression (> or = 10% of the cells) was identified in 68 tumors (37%), and was correlated with high grade histology (P =.002) and Ki-67 proliferative index (r = 0.44; P <.0001), but not with p27 expression (r = -0.02; P =.80). By univariate analysis, high Skp2 expression was associated with decreased metastasis-free, disease-free, and overall survival. In a multivariate model, high Skp2 expression was an independent predictor for decreased local recurrence-free, disease-free, and overall survival. CONCLUSION: These results indicate that Skp2 expression is associated with cell proliferation and a worse prognosis in soft tissue sarcomas. The lack of an inverse correlation between Skp2 and p27 suggests that additional molecular events associated with either Skp2 expression or p27 proteolysis may be operating in these tumors. 相似文献
72.
Francis X Campion George L Tully Jo-Ann Barrett Paulo Andre Ann Sweeney 《Disease management》2005,8(4):245-252
Disease management for chronic conditions is a call for collaboration among all parties of the health care system. The Caritas Christi Health Care System established a unified American Diabetes Association (ADA) recognized outpatient diabetes self-management education program (DSME) in each of its six hospital communities and has established an Internet data portal with managed care organizations to improve preventive care for thousands of patients with diabetes. This article describes the stepwise process of building the successful Caritas Diabetes Care Program and the central role of the Caritas Diabetes Registry over a 5-year period. 相似文献
73.
Anticoagulant Use in Patients with Chronic Renal Impairment 总被引:3,自引:0,他引:3
Patients with renal failure have an increased risk of both thrombotic and bleeding complications. A number of antithrombotic drugs undergo renal clearance. Therefore, estimation of renal function is necessary when prescribing these drugs to patients with renal dysfunction. Pharmacokinetic and clinical data in patients with chronic renal impairment are limited for several anticoagulants, and adequate administration information is often absent. Dose adjustment of anticoagulants may be indicated when the creatinine clearance falls below 30 mL/min. Unfractionated heparin, argatroban, and vitamin K antagonists generally do not require dose adjustment with renal dysfunction. However, smaller doses of warfarin may be required to achieve a particular target international normalized ratio. Close monitoring of anticoagulation is recommended when argatroban or high doses of unfractionated heparin are administered in patients with severe chronic renal impairment. Low-molecular weight heparins, danaparoid sodium, hirudins, and bivalirudin all undergo renal clearance. Lower doses and closer anticoagulation monitoring may be advisable when these agents are used in patients with chronic renal failure. We recommend that fondaparinux sodium and ximelagatran (not yet licensed) be avoided in the presence of severe renal impairment and be used with caution in patients with moderate renal dysfunction. While acknowledging the lack of pharmacokinetic data, this review provides specific recommendations for the use of anticoagulants in patients with chronic renal impairment. 相似文献
74.
Eleftherios P Mamounas Ann Brown Stewart Anderson Roy Smith Thomas Julian Barbara Miller Harry D Bear Christopher B Caldwell Alonzo P Walker Wendy M Mikkelson Jay S Stauffer Andre Robidoux Heather Theoret Atilla Soran Atilla Sovan Bernard Fisher D Lawrence Wickerham Norman Wolmark 《Journal of clinical oncology》2005,23(12):2694-2702
PURPOSE: Experience with sentinel node biopsy (SNB) after neoadjuvant chemotherapy is limited. We examined the feasibility and accuracy of this procedure within a randomized trial in patients treated with neoadjuvant chemotherapy. PATIENTS AND METHODS: During the conduct of National Surgical Adjuvant Breast and Bowel Project trial B-27, several participating surgeons attempted SNB before the required axillary dissection in 428 patients. All underwent lymphatic mapping and an attempt to identify and remove a sentinel node. Lymphatic mapping was performed with radioactive colloid (14.7%), with lymphazurin blue dye alone (29.9%), or with both (54.7%). RESULTS: Success rate for the identification and removal of a sentinel node was 84.8%. Success rate increased significantly with the use of radioisotope (87.6% to 88.9%) versus with the use of lymphazurin alone (78.1%, P = .03). There were no significant differences in success rate according to clinical tumor size, clinical nodal status, age, or calendar year of random assignment. Of 343 patients who had SNB and axillary dissection, the sentinel nodes were positive in 125 patients and were the only positive nodes in 70 patients (56.0%). Of the 218 patients with negative sentinel nodes, nonsentinel nodes were positive in 15 (false-negative rate, 10.7%; 15 of 140 patients). There were no significant differences in false-negative rate according to clinical patient and tumor characteristics, method of lymphatic mapping, or breast tumor response to chemotherapy. CONCLUSION: These results are comparable to those obtained from multicenter studies evaluating SNB before systemic therapy and suggest that the sentinel node concept is applicable following neoadjuvant chemotherapy. 相似文献
75.
Dirk De Ruysscher Stofferinus Wanders Andre Minken Aniek Lumens Jacqueline Schiffelers Cissie Stultiens Serve Halders Liesbeth Boersma Angela van Baardwijk Tom Verschueren Monique Hochstenbag Gabriel Snoep Brad Wouters Sebastiaan Nijsten S?ren M Bentzen Marinus van Kroonenburgh Michel Ollers Philippe Lambin 《Radiotherapy and oncology》2005,77(1):5-10
BACKGROUND AND PURPOSE: To investigate the effect of radiotherapy planning with a dedicated combined PET-CT simulator of patients with locally advanced non-small cell lung cancer. PATIENTS AND METHODS: Twenty-one patients underwent a pre-treatment simulation on a dedicated hybrid PET-CT-simulator. For each patient, two 3D conformal treatment plans were made: one with a CT based PTV and one with a PET-CT based PTV, both to deliver 60Gy in 30 fractions. The maximum tolerable prescribed radiation dose for CT versus PET-CT PTV was calculated based on constraints for the lung, the oesophagus, and the spinal cord, and the Tumour Control Probability (TCP) was estimated. RESULTS: For the same toxicity levels of the lung, oesophagus and spinal cord, the dose could be increased from 55.2+/-2.0Gy with CT planning to 68.9+/-3.3Gy with the use of PET-CT (P=0.002), with corresponding TCP's of 6.3+/-1.5% for CT and 24.0+/-5.6% for PET-CT planning (P=0.01). CONCLUSIONS: The use of a combined dedicated PET-CT-simulator reduced radiation exposure of the oesophagus and the lung, and thus allowed significant radiation dose escalation whilst respecting all relevant normal tissue constraints. 相似文献
76.
Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. 总被引:11,自引:0,他引:11
Andre Goy Anas Younes Peter McLaughlin Barbara Pro Jorge E Romaguera Frederick Hagemeister Luis Fayad Nam H Dang Felipe Samaniego Michael Wang Kristine Broglio Barry Samuels Frederic Gilles Andreas H Sarris Susan Hart Elizabeth Trehu David Schenkein Fernando Cabanillas Alma M Rodriguez 《Journal of clinical oncology》2005,23(4):667-675
PURPOSE: Evaluate efficacy and toxicity of bortezomib in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. PATIENTS AND METHODS: Patients were stratified, based on preclinical data, into arm A (mantle-cell lymphoma) or arm B (other B-cell lymphomas) without limitation in number of prior therapies. Bortezomib was administered as an intravenous push (1.5 mg/m2) on days 1, 4, 8, and 11 every 21 days for a maximum of six cycles. RESULTS: Sixty patients with a median number of prior therapies of 3.5 (range, one to 12 therapies) were enrolled; 33 patients were in arm A and 27 were in arm B, including 12 diffuse large B-cell lymphomas, five follicular lymphomas (FL), three transformed FLs, four small lymphocytic lymphomas (SLL), two Waldenstrom's macroglobulinemias (WM), and one marginal zone lymphoma. In arm A, 12 of 29 assessable patients responded (six complete responses [CR] and six partial responses [PR]) for an overall response rate (ORR) of 41% (95% CI, 24% to 61%), and a median time to progression not reached yet, with a median follow-up of 9.3 months (range, 1.7 to 24 months). In arm B, four of 21 assessable patients responded (one SLL patient had a CR, one FL patient had a CR unconfirmed, one diffuse large B-cell lymphoma patient had a PR, and one WM patient had a PR) for an ORR of 19% (95% CI, 5% to 42%). Grade 3 toxicity included thrombocytopenia (47%), gastrointestinal (20%), fatigue (13%), neutropenia (10%), and peripheral neuropathy (5%). Grade 4 toxicity occurred in nine patients (15%), and three deaths from progression of disease occurred within 30 days of withdrawal from study. CONCLUSION: Bortezomib showed promising activity in relapsed mantle-cell lymphoma and encouraging results in other B-cell lymphomas. Future studies will explore bortezomib in combination with other cytotoxic or biologic agents. 相似文献
77.
Cary Oberije Georgi Nalbantov Andre Dekker Liesbeth Boersma Jacques Borger Bart Reymen Angela van Baardwijk Rinus Wanders Dirk De Ruysscher Ewout Steyerberg Anne-Marie Dingemans Philippe Lambin 《Radiotherapy and oncology》2014
Background
Decision Support Systems, based on statistical prediction models, have the potential to change the way medicine is being practiced, but their application is currently hampered by the astonishing lack of impact studies. Showing the theoretical benefit of using these models could stimulate conductance of such studies. In addition, it would pave the way for developing more advanced models, based on genomics, proteomics and imaging information, to further improve the performance of the models.Purpose
In this prospective single-center study, previously developed and validated statistical models were used to predict the two-year survival (2yrS), dyspnea (DPN), and dysphagia (DPH) outcomes for lung cancer patients treated with chemo radiation. These predictions were compared to probabilities provided by doctors and guideline-based recommendations currently used. We hypothesized that model predictions would significantly outperform predictions from doctors.Materials and methods
Experienced radiation oncologists (ROs) predicted all outcomes at two timepoints: (1) after the first consultation of the patient, and (2) after the radiation treatment plan was made. Differences in the performances of doctors and models were assessed using Area Under the Curve (AUC) analysis.Results
A total number of 155 patients were included. At timepoint #1 the differences in AUCs between the ROs and the models were 0.15, 0.17, and 0.20 (for 2yrS, DPN, and DPH, respectively), with p-values of 0.02, 0.07, and 0.03. Comparable differences at timepoint #2 were not statistically significant due to the limited number of patients. Comparison to guideline-based recommendations also favored the models.Conclusion
The models substantially outperformed ROs’ predictions and guideline-based recommendations currently used in clinical practice. Identification of risk groups on the basis of the models facilitates individualized treatment, and should be further investigated in clinical impact studies. 相似文献78.
79.
Joel Jayaseelan Ashwath Pazhani Anthony Xavior Michael Jeyapandiarajan Paulchamy Andre Batako Prashantha Kumar Hosamane Guruswamy 《Materials》2022,15(17)
From the aspect of exploring the alternative lightweight composite material for the aerospace launch vehicle external fuel tank structural components, the current research work studies three different grades of Aluminium alloy reinforced with varying graphene weight percentages that are processed through powder metallurgy (P/M) route. The prepared green compacts composite ingots are subjected to microwave processing (Sintering), hot extruded, and solution treated (T6). The developed Nano-graphene reinforced composite is studied further for the strength–microstructural integrity. The nature of the graphene reinforcement and its chemical existence within the composite is further studied, and it is found that hot extruded solution treated (HEST) composite exhibited low levels of carbide (Al4C3) formations, as composites processed by microwaves. Further, the samples of different grades reinforced with varying graphene percentages are subjected to mechanical characterisation tests such as the tensile test and hardness. It is found that 2 wt% graphene reinforced composites exhibited enhanced yield strength and ultimate tensile strength. Microstructural studies and fracture morphology are studied, and it is proven that composite processed via the microwave method has exhibited good ductile behaviour and promising failure mechanisms at higher load levels. 相似文献
80.
Shu-Hua Wang Murgesean V. S. Rajaram Andre Trollip Qian Wu Doris Ayala Danyelle Garza Marielena A. Benavidez Kelsie Fox Genesis P. Aguilln-Durn Erika A. Vargas-Orozco Lou Torres Lianbo Yu S. Rumel Ahmed Megan Aspden Thomas Jackson-Soutter Catherine Coxon Ruth Brignall Blanca I. Restrepo 《Journal of clinical microbiology》2022,60(9)